Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift

Backed by an impressive cadre of pharma leaders including Novartis and Pfizer, Mediar Therapeutics added another $85 million to its coffers Wednesday to take its first-in-class fibrosis therapies to the clinic.

Mediar launched in 2019 from Mass Gen Brigham’s extension arm. Pfizer jumped onboard in 2021 in a seed round that brought in $20 million. Novartis Venture Fund co-led the Series A round with Sofinnova Partners. Pfizer, Bristol Myers Squibb, Eli Lilly and Ono Pharmaceutical also participated.

Access the full article on